What medications can prolong International Normalized Ratio (INR) in patients on warfarin?

Medications That Prolong INR in Warfarin Patients

Numerous medications prolong INR through CYP450 enzyme inhibition, protein binding displacement, or alteration of vitamin K metabolism, with antibiotics (particularly trimethoprim-sulfamethoxazole and metronidazole), SSRIs, acetaminophen, and certain chemotherapy agents representing the highest-risk drug classes requiring immediate dose adjustment and intensified monitoring. 1

Antibiotics: The Highest-Risk Class

CYP2C9 Inhibitors

• Trimethoprim-sulfamethoxazole nearly doubles the risk of serious bleeding compared to warfarin alone and requires prophylactic warfarin dose reduction of 25%. 1
• Metronidazole requires prophylactic warfarin dose reduction of 33% when co-administered. 1
• Both agents inhibit CYP2C9, the primary enzyme responsible for warfarin metabolism, leading to accumulation of the more potent S-warfarin isomer 1

Fluoroquinolones and Macrolides

• Ciprofloxacin (strong CYP1A2 inhibitor) increases serum R-warfarin concentrations and elevates INR 1
• Clarithromycin and erythromycin inhibit CYP3A4 (strong and moderate inhibition respectively), potentiating warfarin effects 1
• Large national database registries confirm increased bleeding risk with fluoroquinolones versus warfarin alone 1

Universal Antibiotic Effect

• All antibiotics can alter gut microbiome, which is a rich source of vitamin K, thereby potentiating anticoagulant effects independent of CYP450 interactions. 1
• This mechanism requires close INR monitoring whenever any antibiotic is initiated in chronic warfarin users 1

Psychotropic Medications

SSRIs: Major Bleeding Risk

• Concomitant SSRI use with warfarin more than doubles the risk of bleeding compared to warfarin alone. 1
• Fluvoxamine and fluoxetine deserve special attention as they inhibit both CYP2C9 and CYP3A4; sertraline and citalopram/escitalopram are safer alternatives. 1
• The mechanism involves inhibition of CYP450 enzymes, leading to decreased warfarin clearance 1

Other Psychotropics That Prolong INR

• Quetiapine, valproic acid, entacapone, and tramadol all potentiate warfarin via CYP450 enzyme inhibition 1
• Phenytoin exhibits a biphasic interaction: initially displaces warfarin from protein binding sites (transiently increasing INR), but ultimately induces CYP450 enzymes (decreasing INR long-term). 1

Chemotherapy Agents

Fluoropyrimidines: Extreme Risk

• Fluorouracil increases INR through multiple mechanisms (CYP2C9 inhibition, direct GI tract injury, alteration of GI flora) and requires prophylactic warfarin dose reduction of 20-70%. 1
• Capecitabine increases INR, with decreased warfarin requirements continuing for up to two weeks after discontinuation. 1
• Gemcitabine interacts with warfarin even when administered via intra-bladder instillation 1

Other Chemotherapy Interactions

• Paclitaxel potentiates warfarin by displacing it from protein binding sites 1
• Trastuzumab has been reported in two cases to potentiate warfarin 1

NSAIDs and Analgesics

NSAIDs: Dual Mechanism

• NSAIDs double the risk of bleeding versus warfarin alone through both pharmacodynamic (impaired hemostasis) and pharmacokinetic (protein displacement) mechanisms. 1, 2
• This applies to both non-selective COX and COX-2 selective inhibitors 1
• If NSAID co-administration is unavoidable, using a proton pump inhibitor may reduce GI bleeding risk. 1

Acetaminophen: Dose-Dependent Risk

• Acetaminophen increases INR in a dose-dependent manner, with risk of INR >6 increasing 10-fold once intake exceeds 9.1 grams per week. 1
• At doses >2 g/day, INR increases by an average of 0.7 by day 3, requiring close monitoring during initiation. 1, 3
• The mechanism likely involves pharmacodynamic enhancement of vitamin K antagonism rather than altered warfarin metabolism 3

Cardiovascular Medications

Lipid-Lowering Agents

• Fenofibrate requires close INR monitoring and potential warfarin dose adjustment during initiation 1
• Fish oil (1-2 g/day) can increase INR and has additional antiplatelet effects. 1

Statins

• Certain statins interact with warfarin through CYP450 inhibition, though specific agents vary in interaction potential 2

Miscellaneous High-Risk Agents

Alcohol and Supplements

• Alcohol ingestion inhibits hepatic enzymes and impairs warfarin clearance, significantly increasing INR levels, though modest consumption (~60 gm or 2 ounces/day) appears safe. 1
• Glucosamine may increase INR, with FDA MedWatch database documenting 20 reports of altered coagulation; one case resulted in intraventricular bleed and persistent vegetative state. 4

Azole Antifungals

• High-dose ketoconazole may require warfarin dose reduction exceeding 43% to maintain therapeutic INR. 5
• The mechanism involves potent inhibition of warfarin metabolism 5

Herbal Products

• St. John's wort is well-documented to reduce INR (not prolong), but cranberry, garlic, ginkgo biloba, and dong quai are associated with increased INR. 1, 2
• Cranberry consumption should be limited to ≤24 ounces/day 1

Critical Monitoring Protocol

Timing of INR Checks

• Check INR within 3-5 days of starting any CYP2C9 inhibitor or high-risk medication. 1
• Continue weekly INR monitoring for 2-4 weeks until steady state is reached 1
• When a precipitant drug is initiated in the setting of chronic stable warfarin therapy, patients may develop elevated INR if the interaction goes unrecognized. 1

Common Pitfalls to Avoid

• The order of drug initiation matters: when warfarin is initiated during CYP2C9 inhibitor therapy, supratherapeutic INR may not develop due to frequent monitoring during warfarin initiation phase. 1
• Failing to account for antibiotic effects on gut flora, even with non-CYP450-interacting antibiotics 1
• Not recognizing that some interactions (like acetaminophen) are dose-dependent and may not occur at lower doses 1
• Overlooking over-the-counter supplements and herbal products that patients may not report 1, 2, 4